Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remdesivir for the treatment of COVID-19
Kelly Ansems, Felicitas Grundeis, Karolina Dahms, et al.
Cochrane library (2021) Vol. 2021, Iss. 8
Open Access | Times Cited: 197

Showing 1-25 of 197 citing articles:

Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US
Katherine A. Auger, Samir S. Shah, Troy Richardson, et al.
JAMA (2020) Vol. 324, Iss. 9, pp. 859-859
Open Access | Times Cited: 476
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19
Renato D. Lópes, Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva, et al.
JAMA (2021) Vol. 325, Iss. 3, pp. 254-254
Open Access | Times Cited: 340
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence
Sayeeda Rahman, Maria Teresa Villagomez Montero, Kherie Rowe, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 5, pp. 601-621
Open Access | Times Cited: 258
Ivermectin for preventing and treating COVID-19
Maria Popp, Stefanie Reis, Selina Schießer, et al.
Cochrane library (2022) Vol. 2024, Iss. 3
Open Access | Times Cited: 157
Flavonoids are promising safe therapy against COVID-19
Moza Mohamed Alzaabi, Rania Hamdy, Naglaa S. Ashmawy, et al.
Phytochemistry Reviews (2021) Vol. 21, Iss. 1, pp. 291-312
Open Access | Times Cited: 136
Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies
Gihanna Galindez, Julian Matschinske, Tim Rose, et al.
Nature Computational Science (2021) Vol. 1, Iss. 1, pp. 33-41
Open Access | Times Cited: 114
Remdesivir for the treatment of COVID-19
Felicitas Grundeis, Kelly Ansems, Karolina Dahms, et al.
Cochrane library (2023) Vol. 2023, Iss. 1
Closed Access | Times Cited: 83
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 944-944
Open Access | Times Cited: 70
Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019
M. Martinot, Aude Jary, Samira Fafi‐Kremer, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 7, pp. e1762-e1765
Open Access | Times Cited: 111
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
Mojtaba Shohan, Roohangiz Nashibi, Mohammad‐Reza Mahmoudian‐Sani, et al.
European Journal of Pharmacology (2021) Vol. 914, pp. 174615-174615
Open Access | Times Cited: 88
KG-COVID-19: A Framework to Produce Customized Knowledge Graphs for COVID-19 Response
Justin Reese, Deepak Unni, Tiffany J Callahan, et al.
Patterns (2020) Vol. 2, Iss. 1, pp. 100155-100155
Open Access | Times Cited: 83
Effect of early application of social distancing interventions on COVID-19 mortality over the first pandemic wave: An analysis of longitudinal data from 37 countries
Daniele Piovani, Maria Nefeli Christodoulou, Andreas Hadjidemetriou, et al.
Journal of Infection (2020) Vol. 82, Iss. 1, pp. 133-142
Open Access | Times Cited: 80
Antibiotics for the treatment of COVID-19
Maria Popp, Miriam Stegemann, Manuel Riemer, et al.
Cochrane library (2021) Vol. 2022, Iss. 7
Open Access | Times Cited: 79
Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis
Partha Biswas, Mohammad Mehedi Hasan, Dipta Dey, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 42, pp. 59570-59593
Open Access | Times Cited: 57
Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
Andreas Heyer, Thomas Günther, Alexis Robitaille, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 9, pp. 100735-100735
Open Access | Times Cited: 57
Recent review of COVID-19 management: diagnosis, treatment and vaccination
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1120-1148
Open Access | Times Cited: 55
Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence
Carina Wagner, Mirko Griesel, Agata Mikołajewska, et al.
Cochrane library (2022) Vol. 2022, Iss. 11
Open Access | Times Cited: 55
Janus kinase inhibitors for the treatment of COVID-19
Andre Kramer, Carolin Prinz, Falk Fichtner, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 44
Feline Infectious Peritonitis: European Advisory Board on Cat Diseases Guidelines
Séverine Tasker, Diane Addie, Herman Egberink, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1847-1847
Open Access | Times Cited: 38
Remdesivir: A Review in COVID-19
Hannah A. Blair
Drugs (2023) Vol. 83, Iss. 13, pp. 1215-1237
Open Access | Times Cited: 35
Post-covid-19 conditions in adults: systematic review and meta-analysis of health outcomes in controlled studies
Juan Víctor Ariel Franco, Luis Garegnani, Maria‐Inti Metzendorf, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e000723-e000723
Open Access | Times Cited: 16
Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval
Hee Sun Choi, A Young Choi, Jeffrey B. Kopp, et al.
Journal of Korean Medical Science (2024) Vol. 39, Iss. 14
Open Access | Times Cited: 9
Melatonin is significantly associated with survival of intubated COVID-19 patients
Vijendra Ramlall, Jason Zucker, Nicholas P. Tatonetti
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 53
Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial
Shaukat Ali, Syed Muneeb Uddin, Elisha Shalim, et al.
EClinicalMedicine (2021) Vol. 36, pp. 100926-100926
Open Access | Times Cited: 53
Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019
Ghady Haidar, John W. Mellors
Clinical Infectious Diseases (2021) Vol. 73, Iss. 6, pp. e1397-e1401
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top